Augmentation of cysteamine-induced ulceration of rat duodenum by systemically administered gamma-aminobutyric acid (GABA).
Subcutaneous administration of a single dose of gamma-aminobutyric acid (GABA, 10 mg/100 g) in conjunction with a pretreatment dose of aminooxyacetic acid (AOAA 2.5 mg/100 g subcutaneously) to prevent the degradation of GABA, significantly augmented the incidence and intensity of cysteamine HCl-induced duodenal ulceration in rats. This effect of GABA could be reduced by the GABA receptor antagonist, bicuculline (30 micrograms/100 g subcutaneously). These results suggest peripheral GABA receptors can modulate cysteamine HCl-induced duodenal ulcer.
Krantis
A
A
Department of Physiology, University of Ottawa, Ontario, Canada.
Nicholson
M
M
D000625:Aminooxyacetic Acid / Q000008:administration & dosage / Q000494:pharmacology; D000818:Animals; D001640:Bicuculline / Q000008:administration & dosage / Q000494:pharmacology; D003543:Cysteamine; D004381:Duodenal Ulcer / Q000139:chemically induced / Q000473:pathology*; D018756:GABA Antagonists; D007279:Injections, Subcutaneous; D008297:Male; D051381:Rats; D011919:Rats, Inbred Strains; D011963:Receptors, GABA-A / Q000187:drug effects; D005680:gamma-Aminobutyric Acid / Q000008:administration & dosage / Q000494:pharmacology*
D018756:GABA Antagonists; D011963:Receptors, GABA-A; D000625:Aminooxyacetic Acid; D005680:gamma-Aminobutyric Acid; D003543:Cysteamine; D001640:Bicuculline